JDD Buzz Series | AI in Dermatology Residency Applications: A Program Director’s Perspective
Applicants for dermatology residency programs are increasingly using artificial intelligence (AI) technology to write or enhance their personal statements, according to a study published in the May Journal of Drugs in Dermatology. Is this ethical? Should applicants disclose AI usage? What role, if any, should AI have in applications for programs, positions, and grants?
I interviewed Marjorie Mo …
Applicants for dermatology residency programs are increasingly using artificial intelligence (AI) technology to write or enhance their personal statements, according to a study published in the May Journal of Drugs in Dermatology. Is this ethical? Should applicants disclose AI usage? What role, if any, should AI have in applications for programs, positions, and grants?
I interviewed Marjorie Mo … 
Derm residents, exciting news! The ODAC Dermatology Conference Board Review Workshop Sessions are now live on the Dermatology In-Review website.
If you’re deep in the trenches studying for the upcoming board exams, you know just how valuable these sessions can be. Curated by experts and tailored to align with the high-yield topics you need to know, these workshops are an incredible resource t … 
A 30 year old female at 20 weeks gestation presents with the following rash. She notes a similar rash occurred during her last pregnancy but spontaneously resolved. Which of the following is the most likely diagnosis?
A. Atopic eruption of pregnancy
B. Impetigo herpetiformus
C. Polymorphus eruption of pregnancy
D. Pemphigu … 
Welcome to another installment of "From the JDD Podcast Vault" series! This week, we’re digging into a truly cautionary tale with the episode: Thin Skinned: Topical Steroid Safety and Legal Landmines, hosted by Dr. Adam Friedman and featuring the ever-insightful Dr. Raj Chovatiya.
“Just put some salve on it.” Sounds harmless enough, right? But let’s pause and ask — what could possibl … 
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo …